Published on
May 19, 2026
- 19:04 GMT
FDA Grants INTERACT Meeting for Lead Fabry Disease Program at Glafabra Therapeutics
FDA grants Glafabra an INTERACT meeting for GT-GLA-S03, a cell-based gene therapy designed to replace 130 lifetime Fabry infusions with a single procedure. PARK CITY, UT, UNITED STATES, May 19, 2026 /EINPresswire.com/ -- A High Bar Cleared The FDA has …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
